コンテンツへスキップ
Merck

Pharmacologic treatment of kidney stone disease.

The Urologic clinics of North America (2012-11-28)
Brian H Eisner, David S Goldfarb, Gyan Pareek
要旨

This article reviews the data on pharmacologic treatment of kidney stone disease, with a focus on prophylaxis against stone recurrence. One of the most effective and important therapies for stone prevention, an increase in urine volume, is not discussed because this is a dietary and not a pharmacologic intervention. Also reviewed are medical expulsive therapy used to improve the spontaneous passage of ureteral stones and pharmacologic treatment of symptoms associated with ureteral stents. The goal is to review the literature with a focus on the highest level of evidence (ie, randomized controlled trials).

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
ウレアーゼ Canavalia ensiformis(タチナタマメ)由来, Type III, powder, 15,000-50,000 units/g solid
Sigma-Aldrich
ウレアーゼ Canavalia ensiformis(タチナタマメ)由来, Type IX, powder, 50,000-100,000 units/g solid
Sigma-Aldrich
ウレアーゼ Canavalia ensiformis(タチナタマメ)由来, powder, ~1 U/mg
Sigma-Aldrich
ウレアーゼ Canavalia ensiformis(タチナタマメ)由来, Type III, glycerol solution, 500-800 units/mL
Sigma-Aldrich
ウレアーゼ Canavalia ensiformis(タチナタマメ)由来, Type C-3, powder, ≥600,000 units/g solid
Sigma-Aldrich
ウレアーゼ Canavalia ensiformis(タチナタマメ)由来, powder, white, ~8 U/mg
Sigma-Aldrich
ウレアーゼ Canavalia ensiformis(タチナタマメ)由来